Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 348

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 348
---
 Agrobiotecnología Rosario SA, each holding 33% of Heritas Argentina. On March 31, 2020, Instituto de Agrobiotecnología Rosario SA transferred their shares to Bioceres S.A., marking a significant change in shareholder composition. 178 Bioceres S.A., an affiliate of Theo, endowed Heritas Argentina with a specialized scientific team and the necessary expertise to develop its products and services in the precision medicine industry, as well as critical assistance during the early stages of our subsidiary’s operations in Argentina, ensuring a successful launch into the market, whereas CIBIC contributed with more than 30 years of experience as a laboratory focused on clinical diagnostics and biotechnology development. Heritas Argentina focused its efforts in enabling labs to provide clinical genetic services to physicians and/or healthcare industry stakeholders, looking to transform diagnostics and treatment for patients. Its tests, adapted to the specific needs of the markets in which it operates, range from oncology to prenatal care and rare diseases, and provide precise insights that allow physicians, patients, and their families to become aware of the impact that their genes have on their conditions and how these may affect them in the future. Heritas Argentina primarily derives revenue from its diagnostics division which provides clinical genetic tests relating to the fields of oncology, prenatal care, rare diseases and human microbiome, as well as other genetic sequencing services. On April 14, 2021, all shareholders of Heritas Argentina transferred their shareholding from Heritas Argentina to the Parent (i.e. Bioceres SA, CIBIC, Fabian Fay and Martin Vazquez), resulting in the Parent becoming the sole shareholder of Heritas Argentina. In 2022, after several years providing clinical genetic diagnostic tests in Argentina and expanding these services into Paraguay, Heritas Argentina diversified its product portfolio by launching a new business division. Rewell, a direct -to -consumerbrand, was launched after the COVID -19pandemic, which significantly changed consumer habits by making at -hometesting a routine and making prevention and wellness more relevant to the broader population. Rewell builds on the advances in genetic and gut health testing technology and was designed for general consumers, who seek unique and personalized information to work on their long -termhealth by achieving an optimal lifestyle. Rewell starts with an at -homeDNA and microbiome test kit, and once samples are processed, consumers can view unique insights on their genetic health risks, physical performance, rest and stress, ancestry, nutrition and immunity,